Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers
The Acute Effects of Triacylglycerol Structure of Dietary Fats on Gut Hormones and Haemostatic Markers in Subjects With Type 2 Diabetes Mellitus
2 other identifiers
interventional
23
1 country
5
Brief Summary
Type 2 diabetes mellitus (T2DM) is a chronic disorder determined by lifestyle and genes. It is associated with chronic hyperglycaemia along with other metabolic abnormalities. It is also one of the risk factors for cardiovascular disease (CVD). This disease is due to insulin resistance and/or deficiency as well as increased hepatic glucose output. According to the Third National Health and Morbidity Survey (3rd NHMS), the prevalence of T2DM for adults aged 30 years and above is 14.9%, increased by almost 80% from 1996 to 2006. Dietary composition may affect insulin sensitivity, postprandial triacylglycerol concentration and the risk of T2DM. The role of dietary fats in T2DM is of particular interest and has been clinically studied for many decades. The type of fat we ingest every day consists of different types of fatty acids and different degree of saturation, which in turn influence glucose metabolism by altering cell membrane function, enzyme activity, insulin signalling and gene expression. Previous studies demonstrated that interesterification of dietary fat alter postprandial lipaemia. Saturated fat such as palm olein has been reported to display lower postprandial lipaemia after interesterification. Changing the structure of triacylglycerol (TAG) alters the physical properties of dietary fat which affects digestibility, metabolism and atherogenicity. A recent study conducted by Sanders and co-workers demonstrated reduced levels of plasma glucose-dependent insulinotropic polypeptide (GIP) following both the lard and interesterified palm olein (IPO) compared with the palm olein (PO) and high oleic sunflower oil (HOS) diets in healthy subjects. The GIP and glucagon-like peptide-1 (GLP-1) are major players in the modulation of postprandial insulin secretion by the pancreas. Although GIP secretion in response to meals is normal in patients with Type 2 diabetes mellitus (T2DM), GIP induced secretion of insulin is defective in diabetes. This is observed to be predominantly a defective stimulation of the late phase of insulin response (20-120 minutes). The effect of IPO on GIP may be exaggerated in T2DM patients with impaired insulin sensitivity. Hence, IPO may change the concentrations of gut hormones, postprandial lipaemia, insulinaemic response and CVD related haemostatic markers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable type-2-diabetes-mellitus
Started Sep 2012
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2013
CompletedFirst Submitted
Initial submission to the registry
July 11, 2013
CompletedFirst Posted
Study publicly available on registry
July 24, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedOctober 12, 2015
October 1, 2015
10 months
July 11, 2013
October 9, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP)
To determine the postprandial changes of GIP.
0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour
Secondary Outcomes (5)
6-hour postprandial changes from fasting in gut hormones
0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 h
6-hour postprandial changes from fasting in insulinaemic response
0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour
6-hour postprandial changes from fasting in lipaemia
0, 1, 2, 3, 4, 5, 6 hour for TAG and apoB48; 6 hour postheparin for LPL; pooled 3, 4, 5 hour for chylomicron and PFA
6-hour postprandial changes from fasting in haemostatic response
0, 2, 4, 6 hour for FVIIa, PAI-1 and D-dimer; 0, 4 hour for PWA
6-hour changes from fasting hunger rating using visual analogue scale (VAS)
0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour
Study Arms (3)
Dietary fat - PO
EXPERIMENTALNative palm olein (IV56)
Dietary fat - IPO
EXPERIMENTALChemically interesterified palm olein (IV56)
Dietary fat - HOS
EXPERIMENTALHigh oleic sunflower oil
Interventions
Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
Eligibility Criteria
You may qualify if:
- Mild T2DM individuals not planned for medical intervention
- mmol/L ≤ fasting glucose ≤ 11.1 mmol/L
- % ≤ HbA1c ≤ 9.0%
- Not using antihypertensive, lipid lowering, insulin/glucose modulating medication
- Mild T2DM individuals currently on medical intervention
- Fasting glucose ≤ 11.1 mmol/L
- HbA1c ≤ 9.0%
- Using antihypertensive, lipid lowering or glucose modulating medication
- Malaysian male or female with T2DM aged between 30 to 60 years old
- Not using insulin
- Not having any complications of diabetes
- No medical history of myocardial infarction, angina, thrombosis, stroke or cancer
- Haemoglobin levels for females ≥ 11.5 gm/dl and males ≥ 12.5 gm/dl
- Serum ferritin \> 15 µg/l at commencement of study
You may not qualify if:
- Medical history of myocardial infarction, angina, thrombosis, stroke or cancer
- Underweight (BMI \< 18.5 kg/m²)
- Using insulin
- Total cholesterol \> 7.0 mmol/L
- Abnormal liver function, renal function and haematology
- Hypersensitive towards heparin
- Gastric or lactose intolerance
- Smoker
- Pregnancy and lactating
- Taking alcohol
- Taking alcohol
- Haemoglobin levels for females ≤ 11.5 gm/dl and males ≤ 12.5 gm/dl
- Serum ferritin \< 15 µg/l at commencement of study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Malaysia Palm Oil Boardlead
- Universiti Putra Malaysiacollaborator
- Ministry of Health, Malaysiacollaborator
Study Sites (5)
Malaysian Palm Oil Board (MPOB)
Kajang, Selangor, 43000, Malaysia
Hulu Langat District Health Office
Kajang, Selangor, 43100, Malaysia
Sepang District Health Office
Sepang, Selangor, 43900, Malaysia
Universiti Putra Malaysia
Serdang, Selangor, 43400, Malaysia
Selangor State Health Office
Shah Alam, Selangor, 40100, Malaysia
Related Publications (1)
Mo SY, Lai OM, Chew BH, Ismail R, Bakar SA, Jabbar NA, Teng KT. Interesterified palm olein lowers postprandial glucose-dependent insulinotropic polypeptide response in type 2 diabetes. Eur J Nutr. 2019 Aug;58(5):1873-1885. doi: 10.1007/s00394-018-1738-6. Epub 2018 Jun 5.
PMID: 29872922DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kim Tiu Teng, PhD
Malaysian Palm Oil Board (MPOB)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 11, 2013
First Posted
July 24, 2013
Study Start
September 1, 2012
Primary Completion
July 1, 2013
Study Completion
March 1, 2014
Last Updated
October 12, 2015
Record last verified: 2015-10